

OVERVIEW

- Developing novel therapeutics and diagnostics for infectious diseases, mental health and rare disorders
- Advancing novel use of Bucillamine for COVID-19 and companion long COVID diagnostic
- Novel uses and patch delivery of Psilocybin
- Robust patent portfolio (*16 patents and patent applications*)
- Prioritize development efforts targeting FDA regulatory incentives designations (i.e. Orphan Drug, Fast Track, Breakthrough Therapy and Rare Pediatric Disease)

PRODUCT PIPELINE

Product	Indication	Stage of Development	Regulatory Status
Bucillamine <i>(Oral Tablet)</i>	Infectious Diseases COVID-19	Completed Phase 3	Determining next steps and international opps
Bucillamine <i>(Intravenous)</i>	Rare Inflammatory Disorders Ischemia-reperfusion	Phase 1/2	IND filing for clinical study
Diagnostic Rapid Test	LONG COVID	Pre-commercial prototype	Preparing submission for FDA approval pathway
Oral Psilocybin <i>(Oral Capsule)</i>	Substance Use Disorder Methamphetamine	Phase 1/2	Preparing end-of-Phase 2 meeting with FDA
Psilocybin <i>(Microneedle Patch)</i>	Mental Illness Depression, Anxiety	IND-enabling	IND filing for clinical study

STRATEGIC PARTNERS



EXPECTED MILESTONES Q1-2024

- ▶ Complete reformulation of Bucillamine IV for future studies in infectious diseases and ischemia-reperfusion
- ▶ FDA meeting for Long COVID Lab and Rapid Test development
- ▶ FDA meeting for Bucillamine to treat Long COVID
- ▶ Results of Bucillamine for nerve agent exposure at DRDC
- ▶ Interim results for Phase 1/2 study - Psilocybin in Methamphetamine Disorder at University of Wisconsin
- ▶ FDA pre-IND meeting for Psilocybin patch
- ▶ Initiate IND-enabling studies for MDMA patch

TEAM

Management

Michael Frank, Chairman & CEO
Carmelo Marrelli, CFO
Derrick Welch, COO, Psilocin Pharma

Scientific and Clinical

Dr. Kelly McKee, CSO
Dr. Arshi Kizilbash, M.D.
Dr. Osnesmo Mpanju, Regulatory Affairs
Dr. John Fahy, MD, Clinical and Scientific Advisor
Dr. Douglas Fraser, Scientist, Critical Care Physician

Directors

Michael Frank, William Jackson, Joshua Herman, Christian Scovenna and Andrew Lindzon

CONTACT INFORMATION

Revive Therapeutics Ltd.
82 Richmond Street East
Toronto, ON M5C 1P1

Tel: 1-888-901-0036
E-mail: info@revivether.com
Website: revivether.com

STOCK INFORMATION

Ticker:	CSE: RVV, OTCQB: RVVTF, FRANKFURT: 31R
Share Price:	\$0.03 (Nov 3, 2023)
52-week High / Low:	CAD \$0.275 / \$0.02
Shares Outstanding:	357,646,841
Market Cap:	CAD ~ 10,500,000